← Leaderboards
Riccardo Dalla-Favera
Sloan-Kettering Institute For Cancer Res
$29,692,137
Attributed
$30,582,550
Total exposure
18
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.5M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$66,401,992 · 22
By mechanism
P30$20,849,231 · 5
P01$18,006,593 · 6
R35$9,029,650 · 1
R01$7,455,116 · 6
P50$4,232,965 · 1
R37$4,064,569 · 1
Top collaborators
- Adolfo A. Ferrando5 shared
- Andrew D. Zelenetz2 shared
Most similar at Sloan-Kettering Institute For Cancer Res
Same institution · by research overlap
- Pier Paolo Pandolfi$54,825,346
- Derek B. Sant'angelo$12,312,303
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseProgramsGenesPathogenesisB-LymphocytesTumorS LymphomaCellsTherapeutic TargetMalignant NeoplasmsMutationLymphomaGene ExpressionGeneticStructure Of Germinal Center Of Lymph NodeMolecularLymphomagenesisCancer Center Support GrantLarge Cell Diffuse Non-Hodgkin&AposPathway InteractionsBcl6 GeneIn VivoLeadershipProto-Oncogenes
Grant awards (108)
From pathogenesis to new therapeutic targets in diffuse large B cell lymphoma$987,000
R35 · FY2025 · CA · contact PI
From pathogenesis to new therapeutic targets in diffuse large B cell lymphoma$937,650
R35 · FY2024 · CA · contact PI
From pathogenesis to new therapeutic targets in diffuse large B cell lymphoma$987,000
R35 · FY2023 · CA · contact PI
From pathogenesis to new therapeutic targets in Diffuse Large B cell Lymphoma$940,800
R35 · FY2022 · CA · contact PI
From pathogenesis to new therapeutic targets in Diffuse Large B cell Lymphoma$960,000
R35 · FY2021 · CA · contact PI
MSK SPORE in Lymphoma$2,138,999
P50 · FY2020 · CA
From pathogenesis to new therapeutic targets in Diffuse Large B cell Lymphoma$960,000
R35 · FY2020 · CA · contact PI
MSK SPORE in Lymphoma$2,093,966
P50 · FY2019 · CA
From pathogenesis to new therapeutic targets in Diffuse Large B cell Lymphoma$931,200
R35 · FY2019 · CA · contact PI
From pathogenesis to new therapeutic targets in Diffuse Large B cell Lymphoma$960,000
R35 · FY2018 · CA · contact PI
From pathogenesis to new therapeutic targets in Diffuse Large B cell Lymphoma$960,000
R35 · FY2017 · CA · contact PI
The Role of NOTCH1 in the Pathogenesis of CLL.$358,315
R01 · FY2017 · CA · contact PI
Role of MEF2B mutations in lymphomagenesis$443,555
R01 · FY2016 · CA · contact PI
From pathogenesis to new therapeutic targets in Diffuse Large B cell Lymphoma$406,000
R35 · FY2016 · CA · contact PI
The Role of NOTCH1 in the Pathogenesis of CLL.$358,315
R01 · FY2016 · CA · contact PI
Role of acetyltransferase gene inactivation in follicular lymphoma pathogenesis$332,000
R01 · FY2016 · CA · contact PI
Role of MEF2B mutations in lymphomagenesis$443,555
R01 · FY2015 · CA · contact PI
The Role of NOTCH1 in the Pathogenesis of CLL.$358,315
R01 · FY2015 · CA · contact PI
Role of acetyltransferase gene inactivation in follicular lymphoma pathogenesis$332,000
R01 · FY2015 · CA · contact PI
Role of MEF2B mutations in lymphomagenesis$443,555
R01 · FY2014 · CA · contact PI
The Role of NOTCH1 in the Pathogenesis of CLL.$347,566
R01 · FY2014 · CA · contact PI
Role of acetyltransferase gene inactivation in follicular lymphoma pathogenesis$322,040
R01 · FY2014 · CA · contact PI
The Role of NOTCH1 in the Pathogenesis of CLL.$358,315
R01 · FY2013 · CA · contact PI
Role of acetyltransferase gene inactivation in follicular lymphoma pathogenesis$312,080
R01 · FY2013 · CA · contact PI
SENIOR LEADERSHIP$136,394
P30 · FY2013 · CA · contact PI
PROGRAM LEADERS$136,392
P30 · FY2013 · CA · contact PI
DEVELOPMENTAL FUNDS$136,392
P30 · FY2013 · CA · contact PI
PROGRAM PLANNING AND EVALUATION$136,392
P30 · FY2013 · CA · contact PI
Role of acetyltransferase gene inactivation in follicular lymphoma pathogenesis$332,000
R01 · FY2012 · CA · contact PI
DEVELOPMENTAL FUNDS$317,991
P30 · FY2012 · CA · contact PI
PROGRAM LEADERS$252,927
P30 · FY2012 · CA · contact PI
SENIOR LEADERSHIP$211,166
P30 · FY2012 · CA · contact PI
PROGRAM PLANNING AND EVALUATION$20,991
P30 · FY2012 · CA · contact PI
AIDS Associated Lymphoproliferative Disorders$390,425
R37 · FY2011 · CA · contact PI
DEVELOPMENTAL FUNDS$355,067
P30 · FY2011 · CA · contact PI
PROGRAM LEADERS$282,415
P30 · FY2011 · CA · contact PI
SENIOR LEADERSHIP$235,787
P30 · FY2011 · CA · contact PI
PROGRAM PLANNING AND EVALUATION$23,435
P30 · FY2011 · CA · contact PI
Cancer Center Support Grant$4,017,288
P30 · FY2010 · CA · contact PI
The Role of BCL-6 in Berminal Center Formation$478,231
P01 · FY2010 · CA · contact PI
AIDS Associated Lymphoproliferative Disorders$402,500
R37 · FY2010 · CA · contact PI
DEVELOPMENTAL FUNDS$362,630
P30 · FY2010 · CA · contact PI
PROGRAM LEADERS$288,431
P30 · FY2010 · CA · contact PI
SENIOR LEADERSHIP$240,809
P30 · FY2010 · CA · contact PI
Cancer Center Support Grant$100,000
P30 · FY2010 · CA · contact PI
PROGRAM PLANNING AND EVALUATION$23,934
P30 · FY2010 · CA · contact PI
Cancer Center Support Grant$3,999,822
P30 · FY2009 · CA · contact PI
The Role of BCL-6 in Berminal Center Formation$473,903
P01 · FY2009 · CA · contact PI
AIDS Associated Lymphoproliferative Disorders$402,500
R37 · FY2009 · CA · contact PI
DEVELOPMENTAL FUNDS$361,086
P30 · FY2009 · CA · contact PI
CORE--REGULATORY MODULES IN NORMAL AND TRANSFORMED B-CELLS$331,058
U54 · FY2009 · CA · contact PI
PROGRAM LEADERS$287,203
P30 · FY2009 · CA · contact PI
Cancer Center Support Grant$266,990
P30 · FY2009 · CA · contact PI
SENIOR LEADERSHIP$239,784
P30 · FY2009 · CA · contact PI
Cancer Center Clinical Trials Reporting Program (CTRP) Early Adopters$99,928
P30 · FY2009 · CA · contact PI
Cancer Center Support Grant$50,008
P30 · FY2009 · CA · contact PI
PROGRAM PLANNING AND EVALUATION$23,832
P30 · FY2009 · CA · contact PI
DEVELOPMENTAL FUNDS$4,405
P30 · FY2009 · CA · contact PI
PROGRAM LEADERS$3,502
P30 · FY2009 · CA · contact PI
SENIOR LEADERSHIP$2,924
P30 · FY2009 · CA · contact PI
PROGRAM PLANNING AND EVALUATION$290
P30 · FY2009 · CA · contact PI
Cancer Center Support Grant$3,785,244
P30 · FY2008 · CA · contact PI
AIDS Associated Lymphoproliferative Disorders$432,500
R37 · FY2008 · CA · contact PI
The Role of BCL-6 in Berminal Center Formation$399,230
P01 · FY2008 · CA · contact PI
Role of BCL6 Mutation in Lymphomagenesis$317,808
R01 · FY2008 · CA · contact PI
CORE--REGULATORY MODULES IN NORMAL AND TRANSFORMED B-CELLS$281,502
U54 · FY2008 · CA · contact PI
DEVELOPMENTAL FUNDS$219,766
P30 · FY2008 · CA · contact PI
PROGRAM LEADERS$174,799
P30 · FY2008 · CA · contact PI
SENIOR LEADERSHIP$145,939
P30 · FY2008 · CA · contact PI
PROGRAM PLANNING AND EVALUATION$14,505
P30 · FY2008 · CA · contact PI
Molecular Pathogenesis of Breast Cancer$2,574,847
P01 · FY2007 · CA · contact PI
AIDS Associated Lymphoproliferative Disorders$402,500
R37 · FY2007 · CA · contact PI
The Role of BCL-6 in Berminal Center Formation$389,171
P01 · FY2007 · CA · contact PI
Role of BCL6 Mutation in Lymphomagenesis$317,808
R01 · FY2007 · CA · contact PI
CORE--REGULATORY MODULES IN NORMAL AND TRANSFORMED B-CELLS$251,897
U54 · FY2007 · CA · contact PI
Molecular Pathogenesis of Breast Cancer$2,590,529
P01 · FY2006 · CA · contact PI
Cancer Center Support Grant$1,841,557
P30 · FY2006 · CA · contact PI
AIDS Associated Lymphoproliferative Disorders$399,144
R37 · FY2006 · CA · contact PI
The Role of BCL-6 in Berminal Center Formation$378,918
P01 · FY2006 · CA · contact PI
Role of BCL6 Mutation in Lymphomagenesis$327,299
R01 · FY2006 · CA · contact PI
CORE--REGULATORY MODULES IN NORMAL /TRANSFORMED B-CELLS$166,551
U54 · FY2006 · CA · contact PI
Molecular Pathogenesis of Breast Cancer$2,592,021
P01 · FY2005 · CA
Cancer Center Support Grant$1,841,557
P30 · FY2005 · CA
AIDS Associated Lymphoproliferative Disorders$408,750
R37 · FY2005 · CA
Role of BCL6 Mutation in Lymphomagenesis$335,175
R01 · FY2005 · CA
Cancer Center Support Grant$207,649
P30 · FY2005 · CA
CORE--REGULATORY MODULES IN NORMAL /TRANSFORMED B-CELLS$167,509
U54 · FY2005 · CA
Molecular Pathogenesis of Breast Cancer$2,563,491
P01 · FY2004 · CA
AIDS Associated Lymphoproliferative Disorders$408,750
R37 · FY2004 · CA
Role of BCL6 Mutation in Lymphomagenesis$335,175
R01 · FY2004 · CA
Molecular Pathogenesis of Breast Cancer$2,505,821
P01 · FY2003 · CA
Cell, Molecular and Developmental Biology of Cancer$477,431
T32 · FY2003 · CA
AIDS Associated Lymphoproliferative Disorders$408,750
R37 · FY2003 · CA
Cell, Molecular and Developmental Biology of Cancer$410,440
T32 · FY2002 · CA
AIDS Associated Lymphoproliferative Disorders$408,750
R37 · FY2002 · CA
BCL6 IN GERMINAL CENTER FORMATION AND LYMPHOMAGENESIS$0
P01 · FY2002 · CA
TUMOR SUPPRESSORS INVOLVED IN MULTIPLE TUMOR TYPES$1,280,222
P01 · FY2001 · CA
Cell, Molecular and Developmental Biology of Cancer$404,080
T32 · FY2001 · CA
AIDS ASSOCIATED LYMPHOPROLIFERATIVE DISORDERS$356,721
R01 · FY2001 · CA
HYPERMUTATION OF BCL6 REGULATORY SEQUENCES IN NONHODGKIN'S LYMPHOMA$76,744
P01 · FY2001 · CA
BCL6 IN GERMINAL CENTER FORMATION AND LYMPHOMAGENESIS$0
P01 · FY2001 · CA
CLONING OF THE 6Q27 TUMOR SUPPRESSOR GENE$0
P01 · FY2001 · CA
TUMOR SUPPRESSORS INVOLVED IN MULTIPLE TUMOR TYPES$1,269,503
P01 · FY2000 · CA
C-MYC REARRANGEMENTS IN HEMATOPOIETIC NEOPLASIAS$375,338
R01 · FY2000 · CA
AIDS ASSOCIATED LYMPHOPROLIFERATIVE DISORDERS$348,181
R01 · FY2000 · CA
CELL, MOLECULAR AND DEVELOPMENTAL BIOLOGY OF CANCER$273,400
T32 · FY2000 · CA
CLONING OF THE 6Q27 TUMOR SUPPRESSOR GENE$250,910
P01 · FY2000 · CA
HYPERMUTATION OF BCL6 REGULATORY SEQUENCES IN NONHODGKIN'S LYMPHOMA$183,052
P01 · FY2000 · CA